Please Wait
Applying Filters...
menu
    • menu
    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2026 highlights: Astra, CSPC sign up to US$ 18.5 bn obesity deal; Wegovy’s pill version debuts in US

    Stock Recap
    #PipelineProspector

    Menu

    Tafasitamab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Labeler NDC Package Code Non Proprietary Name Start Marketing Date End Marketing Date Category Code Dosage Form (Strength)
    29/01/2026 Boehringer Ingelheim GmbH
    Germany
    		 Boehringer Ingelheim Pharma GmbH and Co. KG 12714-219 Tafasitamab 2020-07-31 2026-12-31 DRUG FOR FURTHER PROCESSING POWDER (200mg/200mg)
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.